Based on the Taysha Gene Therapies Inc stock forecast from 7 analysts, the average analyst target price for Taysha Gene Therapies Inc is USD 6.82 over the next 12 months. Taysha Gene Therapies Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Taysha Gene Therapies Inc is Bearish, which is based on 1 positive signals and 7 negative signals. At the last closing, Taysha Gene Therapies Inc’s stock price was USD 2.70. Taysha Gene Therapies Inc’s stock price has changed by +26.76% over the past week, +117.74% over the past month and -12.62% over the last year.
No recent analyst target price found for Taysha Gene Therapies Inc
No recent average analyst rating found for Taysha Gene Therapies Inc
Company Overview Taysha Gene Therapies Inc
Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. The company has research, collaboration, and license agreement with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas. Read Less
Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of gi...Read More
Frequently Asked Questions About Taysha Gene Therapies Inc (TSHA) Stock
Based on ratings from 7 analysts Taysha Gene Therapies Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 11 buy, sell and hold ratings.
Unfortunately we do not have enough data on TSHA's stock to indicate if its a good dividend stock.
Based on targets from 7 analysts, the average taret price for TSHA is USD 6.82 over the next 12 months. The maximum analyst target price is USD 9 while the minimum anlayst target price is USD 5.
TSHA stock's Price/Earning ratio is 2.65.
Our analysis grades TSHA stock's Price / Earning ratio at D-. This means that TSHA stock's Price/Earning ratio is above 39% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this TSHA may be fairly valued for its sector
The last closing price of TSHA's stock was USD 2.70.
The most recent market capitalization for TSHA is USD 0.26B.
Based on targets from 7 analysts, the average taret price for TSHA is projected at USD 6.82 over the next 12 months.
This means that TSHA's stock price may go up by +152.53% over the next 12 months.
We can't find any ETFs which contains Taysha Gene Therapies Inc's stock.
As per our most recent records Taysha Gene Therapies Inc has 73 Employees.
Taysha Gene Therapies Inc's registered address is 3000 Pegasus Park Drive, Dallas, TX, United States, 75247.
You can get more information about it from Taysha Gene Therapies Inc's website at https://www.tayshagtx.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Superior capital utilization
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Highly leveraged
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
Frequently Asked Questions About Taysha Gene Therapies Inc (TSHA) Stock
Based on ratings from 7 analysts Taysha Gene Therapies Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 11 buy, sell and hold ratings.
Unfortunately we do not have enough data on TSHA's stock to indicate if its a good dividend stock.
Based on targets from 7 analysts, the average taret price for TSHA is USD 6.82 over the next 12 months. The maximum analyst target price is USD 9 while the minimum anlayst target price is USD 5.
TSHA stock's Price/Earning ratio is 2.65.
Our analysis grades TSHA stock's Price / Earning ratio at D-. This means that TSHA stock's Price/Earning ratio is above 39% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this TSHA may be fairly valued for its sector
The last closing price of TSHA's stock was USD 2.70.
The most recent market capitalization for TSHA is USD 0.26B.
Based on targets from 7 analysts, the average taret price for TSHA is projected at USD 6.82 over the next 12 months.
This means that TSHA's stock price may go up by +152.53% over the next 12 months.
We can't find any ETFs which contains Taysha Gene Therapies Inc's stock.
As per our most recent records Taysha Gene Therapies Inc has 73 Employees.
Taysha Gene Therapies Inc's registered address is 3000 Pegasus Park Drive, Dallas, TX, United States, 75247.
You can get more information about it from Taysha Gene Therapies Inc's website at https://www.tayshagtx.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for TSHA !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
